139 related articles for article (PubMed ID: 38357786)
1. TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling.
Marugán C; Sanz-Gómez N; Ortigosa B; Monfort-Vengut A; Bertinetti C; Teijo A; González M; Alonso de la Vega A; Lallena MJ; Moreno-Bueno G; de Cárcer G
Mol Oncol; 2024 Jun; 18(6):1531-1551. PubMed ID: 38357786
[TBL] [Abstract][Full Text] [Related]
2. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
3. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
4. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer.
Shen J; Cao B; Wang Y; Ma C; Zeng Z; Liu L; Li X; Tao D; Gong J; Xie D
J Exp Clin Cancer Res; 2018 Jul; 37(1):175. PubMed ID: 30055645
[TBL] [Abstract][Full Text] [Related]
5. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
[TBL] [Abstract][Full Text] [Related]
6. [YAP induces chromosomal instability in liver cancer patients].
Weiler S
Pathologe; 2018 Dec; 39(Suppl 2):185-188. PubMed ID: 30206654
[TBL] [Abstract][Full Text] [Related]
7. Integrin signalling regulates YAP and TAZ to control skin homeostasis.
Elbediwy A; Vincent-Mistiaen ZI; Spencer-Dene B; Stone RK; Boeing S; Wculek SK; Cordero J; Tan EH; Ridgway R; Brunton VG; Sahai E; Gerhardt H; Behrens A; Malanchi I; Sansom OJ; Thompson BJ
Development; 2016 May; 143(10):1674-87. PubMed ID: 26989177
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells.
Fu J; Liu W; Liu S; Zhao R; Hayashi T; Zhao H; Xiang Y; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Cell Signal; 2024 Jul; 119():111186. PubMed ID: 38643945
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
10. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
11. Targeting YAP in malignant pleural mesothelioma.
Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
[TBL] [Abstract][Full Text] [Related]
12. Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer.
Chen M; Zhang H; Zhang G; Zhong A; Ma Q; Kai J; Tong Y; Xie S; Wang Y; Zheng H; Guo L; Lu R
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):74-82. PubMed ID: 30454896
[TBL] [Abstract][Full Text] [Related]
13. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
15. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications.
Maugeri-Saccà M; Barba M; Pizzuti L; Vici P; Di Lauro L; Dattilo R; Vitale I; Bartucci M; Mottolese M; De Maria R
Expert Rev Mol Med; 2015 Jul; 17():e14. PubMed ID: 26136233
[TBL] [Abstract][Full Text] [Related]
16. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
[TBL] [Abstract][Full Text] [Related]
18. m
Wu J; Yi T; Zhuo C; Wang D; Zhang M; Hu R; Wu D; Hou G; Xing Y
J Cell Physiol; 2024 May; 239(5):e31220. PubMed ID: 38372068
[TBL] [Abstract][Full Text] [Related]
19. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
[TBL] [Abstract][Full Text] [Related]
20. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
